.png){kind=icon}
.png){kind=icon}
Return
Pembrolizumab plus lenvatinib for previously untreated advanced non-clear cell renal cell carcinoma: 3-year follow-up of the phase 2 KEYNOTE-B61 study
.png){kind=icon}
OA
AI
DOI：10.1093/oncolo/oyaf276.002.png)
.png){kind=icon}
.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En
Keywords:
immunotherapy
renal cell carcinoma
non-clear cell renal cell carcinoma
pembrolizumab
lenvatinib
AI Summary
Key information extracted from the uploaded paper, including a brief overview, abstract, background, key highlights, visual analysis, and future outlook.
Journal
IF:
4.2
Papers:
642
Citations:
1.8W
View more organizations